H. Shi

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.

J. Leonard, S. de Vos, R. Fisher, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

I. Flinn, A. Krishnan, P. Richardson, 2010, Leukemia.

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

G. Lou, Xuehao Wang, X. Wu, 2020 .

Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.

W. Tap, P. Rutkowski, M. von Mehren, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Bortezomib in relapsed or refractory mantle cell lymphoma (MCL): Results of the PINNACLE study.

R. Fisher, B. Djulbegovic, A. Boral, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody.

D. Olive, M. Cragg, M. Bi, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

MA02.02 Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

Y. Wu, Y. Sun, G. Wu, 2021, Journal of Thoracic Oncology.

Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

B. Cheson, S. Parasuraman, P. Rosen, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.